Servier Stumbles in Muscle Disease as Drug From $1.5B Deal Fails Pivotal Test
Servier’s sevasemten got here from the acquisition of the muscular dystrophy belongings of Edgewise Therapeutics. Whereas the small molecule had ...
Servier’s sevasemten got here from the acquisition of the muscular dystrophy belongings of Edgewise Therapeutics. Whereas the small molecule had ...
The French pharma Servier stated Tuesday that an experimental drug it bought in June for $1.55 billion in money, plus ...
A Bausch + Lomb drug from a 2025 acquisition missed main and secondary objectives of a Section 2 take a ...
When clinics choose an AI companion – particularly for AI Voice Brokers – the expectation is that the device will ...
Ampreloxetine’s Section 3 failure in a number of system atrophy is the third disappointing medical trial end result for the ...
The outcomes of a randomized managed trial (RCT) point out that meningococcal B vaccine isn't efficient at stopping gonorrhea an ...
A new UCLA study reveals that a widely used federal hospital safety metric is fundamentally flawed when applied to emergency ...
Frerieke / Flickr cc A randomized clinical trial finds that the anti-inflammatory drug colchicine, once thought promising for treating COVID-19, ...
An experimental drug from Alector Inc. failed to slow the decline of patients with frontotemporal dementia in a late-stage study, ...
A Bristol Myers Squibb drug whose landmark FDA approval introduced the first novel mechanism for treating schizophrenia in decades has ...
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.